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Abstract. Fibroblast growth factor receptor 2 (FGFR2) is 
thought to mediate an important signaling pathway between 
prostate epithelial cells and stromal cells for maintenance 
of homeostasis in normal prostate tissue. Abnormalities 
of FGFR2 have been shown in advanced prostate cancer or 
prostate cancer cell lines, and we previously demonstrated 
the tumor-suppressive effects of the restoration of FGFR2IIIb 
in prostate cancer cells. The aim of the present study was to 
determine whether FGFR2IIIb plays a role in the chemosensi-
tivity of castration-resistant prostate cancer cells. A clonal line 
of PC-3 cells expressing FGFR2IIIb (PC-3R2IIIb) was estab-
lished by transfection with an IRESneo2-expressing vector 
bearing FGFR2IIIb cDNA. The effects of chemotherapeutic 
agents (docetaxel, cisplatin, 5-fluorouracil and zoledronic 
acid) on cell viability and apoptosis were examined by MTT 
assay and western blot analysis, respectively. Expression levels 
of molecules that were markers of epithelial-to-mesenchymal 
transition and chemosensitivity-related proteins were assessed 
by western blot analysis. Viability of the PC-3R2IIIb cells 
was significantly lower than that of the control PC-3 cells 
transfected with the vector alone (PC-3neo), and viability was 
further suppressed by treatment with chemotherapeutic agents, 
particularly docetaxel. Induced expression of caspase-3 was 
evident in the PC-3R2IIIb cells and was further enhanced by 
treatment with docetaxel. Expression of N-cadherin, vimentin, 
survivin and XIAP was lower in the PC-3R2IIIb cells than 
that in the PC-3neo cells. In contrast, expression of p21 was 
higher in the PC-3R2IIIb cells than that in the control PC-3neo 
cells. These data indicate that restoration of FGFR2IIIb in 
castration-resistant prostate cancer cells may reverse some of 
the epithelial-to-mesenchymal cell properties characteristic of 
tumor cells and induce in part mesenchymal-to-epithelial tran-
sition properties. This together with enhancement of apoptotic 
pathways involving caspase-3 may enhance chemosensitivity 
particularly to docetaxel which is widely used in the treatment 
of castration-resistant prostate cancer.
Introduction
Prostate cancer is one of the most common malignant 
neoplasms among men and is the second leading cause of male 
cancer-related death in the United States (1-3). Most prostate 
cancers initially show characteristics of androgen-dependent 
growth and are sensitive to androgen deprivation therapy 
(ADT). However, these cancers eventually acquire the ability 
of castration-resistant growth and become resistant to ADT (4). 
Although chemotherapy that includes docetaxel has been 
regarded as an effective choice in the clinical strategy against 
castration-resistant prostate cancer (CRPC), its anticancer 
effect alone appears insufficient (5). Eventually, resistance to 
chemotherapy develops, and disease control becomes even 
more difficult. Clarification of molecular mechanisms in 
CRPC for development of novel therapeutic strategies against 
this resistant cancer remains a high priority.
Fibroblast growth factor (FGF) signaling has been impli-
cated in cellular homeostasis in normal prostate tissue by 
mediating communication between epithelial and stromal 
cells (6-8). FGF receptor type 2IIIb (FGFR2IIIb) is one of the 
splicing variants of FGFR2 generally associated with differ-
entiated epithelial cells and is expressed in prostate epithelial 
cells. It is specific for FGF7 (keratinocyte growth factor, KGF) 
and FGF10, which when expressed are associated with stromal 
cells (6,9-16). Prostate stromal cells secrete FGF7 or FGF10 
in response to androgen stimulation, and signals elicited by 
their activation of FGFR2IIIb have been correlated with cell 
growth, cell differentiation or apoptosis (6,12,16-18). The 
loss or abnormalities of FGFR2IIIb expression have been 
demonstrated in prostate cancer, especially in progressive 
or castration-resistant cancers (15-21). Previous studies have 
shown that restoration of FGFR2IIIb in prostate cancer cells 
leads to suppression of cell growth through KGF-FGFR2IIIb 
Restoration of fibroblast growth factor receptor 2IIIb enhances 
the chemosensitivity of human prostate cancer cells
KOICHI SHOJI1,  JUN TEISHIMA1,  TETSUTARO HAYASHI1,  SHINYA OHARA1, 
WALLACE L. McKEEHAN2  and  AKIO MATSUBARA1
1Department of Urology, Institute of Biomedical and Health Sciences, Integrated Health Science, 
Hiroshima University, Hiroshima 734-8551, Japan; 2Center for Cancer and Stem Cell Biology, 
Institute of Bioscience and Technology, Texas A&M Health Science Center, Houston, TX 77030, USA
Received February 5, 2014;  Accepted April 23, 2014
DOI: 10.3892/or.2014.3200
Correspondence to: Dr Jun Teishima, Department of Urology, 
Institute of Biomedical and Health Sciences, Integrated Health 
Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 
734-8551, Japan
E-mail: teishima@hiroshima-u.ac.jp
Key words: fibroblast growth factor receptor 2IIIb, prostate cancer, 
docetaxel, chemosensitivity
SHOJI et al:  ROLE OF FGFR2IIIb IN THE CHEMOSENSITIVITY OF CRPC66
signaling, induction of apoptosis and generally tumor-
suppressive effects in vivo (18,19). These reports suggest that 
disorders of the KGF-FGFR2IIIb signaling pathway may 
be an important event for CRPC to acquire greater growth 
potential and tumorigenic properties. This suggests that the 
manipulation of FGFR2IIIb or its tumor-suppressive pathways 
deserves attention as a novel therapeutic target. In addition to 
this evidence of the effects of the KGF-FGFR2IIIb signaling 
pathway, several studies have shown the involvement of the 
FGF system in chemoresistance in malignant cells (22). In the 
present study, we investigated the effects of the restoration of 
FGFR2IIIb on the chemosensitivity of CRPC cells as a guide 
for possible development of new therapeutic strategies and 
biomarkers of their efficacy for CRPC.
Materials and methods
Cell culture and transfections. The PC-3 cell line is one of 
the representative prostate cancer cell lines with the ability for 
castration-resistant growth (23). Several studies have shown 
its unresponsiveness to hormones and resistance to apop-
tosis (23-25). In PC-3 cells, abnormalities of FGF and FGFR 
expression including the loss of FGFR2IIIb expression have 
been demonstrated (18). For these reasons, we used PC-3 cells 
in the present study.
Cloned PC-3 cells were maintained in OPTI-MEM1 
medium (Life Technologies, Carlsbad, CA, USA) supple-
mented with 5% heat-inactivated fetal bovine serum 
(FBS; Life Technologies) and 100 mg/ml kanamycin (Life 
Technologies). Preparation of FGFR2IIIb cDNA and trans-
fection to PC-3 cells have been previously described (18). 
Briefly, full-length FGFR2IIIb cDNA was cloned into the 
IRESneo2 expression vector (Clontech Laboratories, Inc., 
Palo Alto, CA, USA) (IRESneo2-FGF2IIIb). PC-3 cells were 
transfected with IRESneo2-FGFR2IIIb or the IRESneo2 
empty control vector by electroporation using the Gene Pulser 
II apparatus (Bio-Rad Laboratories, Hercules, CA, USA). The 
cells were suspended and incubated in OPTI-MEM1 medium 
supplemented with 5% heat-inactivated FBS and 100 mg/ml 
kanamycin containing 200 mg/ml G418 sulfate (Promega, 
Madison, WI, USA) for 14 days. Colonies of cells were picked 
up and maintained in medium containing 200 mg/ml of G418 
sulfate. Expression of FGFR2IIIb was analyzed by western 
immunoblotting with mouse anti-FGFR2IIIb antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA). PC-3 cell lines 
transfected with FGFR2IIIb were designated as PC-3R2IIIb, 
and control cell cultures transfected with empty vector were 
designated as PC-3neo.
Assessment of cell viability. Cell viability and indirectly cell 
numbers were measured with the MTT assay. PC-3R2IIIb and 
PC-3neo cells (1,000 cells/well) were each plated in 96-well 
plates containing 100 µl of OPTI-MEM1 medium and 5% 
heat-inactivated FBS and incubated at 37˚C under 5% CO2 
overnight. To determine the cytotoxic effect of chemothera-
peutic agents, cells were treated with a range of concentrations 
of docetaxel, cisplatin, 5-fluorouracil or zoledronic acid. After 
1 h, cells in each well were washed with phosphate-buffered 
saline (PBS) and incubated in 100 µl of OPTI-MEM1 medium 
plus 5% heat-inactivated FBS. On days 2 and 4, the MTT solu-
tion was added followed by incubation at 37˚C for 4 h. Cell 
viability was measured using an ELISA plate reader (Bio-Rad 
Laboratories) at 570 nm with the reference wavelength of 
630 nm.
Assessment of biomarker expression. Western blot analysis 
was performed essentially as previously described (18). The 
following antibodies were used at dilutions of 1:1,000: anti-
caspase-3 rabbit monoclonal antibody (#9662; Cell Signaling 
Technology, Beverly, MA, USA), anti-p53 mouse monoclonal 
antibody (#2015; Cell Signaling Technology), anti-p21 rabbit 
monoclonal antibody (ab7960; Abcam, Cambridge, MA, USA), 
anti-N-cadherin rabbit monoclonal antibody (ab1221; Abcam), 
anti-E-cadherin rabbit monoclonal antibody (ab53033; Abcam), 
anti-vimentin mouse monoclonal antibody (ab115191; Abcam), 
anti-MDR1 monoclonal antibody (clone C219; Calbiochem, 
Darmstadt, Germany), anti-clusterin rabbit polyclonal antibody 
(GTX101236; GeneTex, Irvine, CA, USA), anti-Bcl-2 rabbit 
polyclonal antibody (GTX101291; GeneTex), anti-Bcl2-like 1 
rabbit polyclonal antibody (GTX105661; GeneTex), anti-
Mdm2 p53 binding protein homolog (mouse) rabbit polyclonal 
antibody (GTX100654; GeneTex), anti-X-linked inhibitor of 
apoptosis rabbit polyclonal antibody (GTX113130; GeneTex), 
anti-baculoviral IAP repeat containing 5 rabbit polyclonal 
antibody (GTX100052; GeneTex) and anti-CYP3A4 rabbit 
polyclonal antibody (GTX101236; GeneTex). The membrane 
was stripped and reprobed with an anti-β-actin mouse mono-
clonal antibody (A5441; Sigma-Aldrich, St. Louis, MO, USA), 
to verify loading and transfer.
Knockdown of p21 by RNA interference. Short interfering 
RNA (siRNA) oligonucleotides for p21 and a negative control 
were purchased from Invitrogen (Carlsbad, CA, USA). Three 
independent oligonucleotides were used for p21 siRNA as 
follows: a p21 siRNA1 sequence, 5'-GAU GUC CGU CAG 
AAC CCA UGC GGC A-3'; a p21 siRNA2 sequence, 5'-UGC 
CGC AUG GGU UCU GAC GGA CAU C-3'; and a p21 
siRNA3 sequence, 5'-UGA GCC GCG ACU GUG AUG CGC 
UAA U-3'. Transfection was carried out using Lipofectamine 
RNAiMAX (Invitrogen) according to the manufacturer's 
protocol. Briefly, 60 pmol of siRNA and 10 µl of Lipofectamine 
RNAiMAX were mixed in 1 ml of RPMI medium (10 nmol/l 
final siRNA concentration). After 20 min of incubation, the 
mixture was added to the cells, and these cells were plated on 
dishes for each assay. Cells were analyzed for all experiments 
at 48 h after transfection.
Statistical analysis. The results of the MTT assay were 
analyzed using the Mann-Whitney U test. All statistical 
analyses were conducted using StatView 5.0 software package 
(SAS Institute, Inc., Cary, NC, USA). A P-value of <0.05 was 
considered to be a statistically significant result.
Results
FGFR2IIIb causes reduced viability and mesenchymal 
markers while enhancing caspase-3 in PC-3 cells. To inves-
tigate a potential effect of FGFR2IIIb on chemosensitivity, 
we expressed FGFR2IIIb in PC-3 cells by transfection. 
Analysis of the survival of FGFR2IIIb-transfected PC-3 
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cells (PC-3R2IIIb) over time with the MTT assay indicated a 
significantly lower viability than that of the cells mock trans-
fected with the empty transfection vector (PC-3neo) (Fig. 1A). 
Expression of N-cadherin and vimentin were concurrently 
suppressed while that of caspase-3 was enhanced due to resto-
ration of expression of FGFR2IIIb in PC-3 cells (Fig. 1B).
FGFR2IIIb enhances the chemosensitivity of PC-3 cells. To 
investigate whether restoration of FGFR2IIIb influences the 
anticancer effect of chemotherapeutic agents, the cell viabili-
ties of PC-3neo and PC-3R2IIIb cells were compared after 
treatment with various anticancer agents (Fig. 2). Viability 
of cells expressing FGFR2IIIb was even lower than that of 
the control PC-3neo cells after treatment with all chemo-
therapeutic agents. The viability of the PC-3R2IIIb cells was 
suppressed by concentrations of cisplatin, 5-fluorouracil and 
zoledronic acid that were 10% that required to suppress the 
viability of the PC-3neo cells to a similar extent. Suppression 
of viability by docetaxel was even more notable. Docetaxel 
was effective at 1% of the concentration in the PC-3R2IIIb 
cells required to similarly suppress the viability of PC-3neo 
cells. A significant dose-dependent growth-suppressive effect 
was observed in the PC-3R2IIIb cells with as little as 0.01 
or 0.10 µM of docetaxel (P=0.045 in 0.1 µM and P=0.045 in 
0.01 µM, respectively). Docetaxel concurrently increased the 
expression of caspase-3 in a dose-dependent manner (Fig. 3). 
These data suggest that restoration of FGFR2IIIb enhances the 
chemosensitivity in prostate cancer cells through the induction 
of increased apoptosis.
FGFR2IIIb effect on biomarkers related to docetaxel chemo-
sensitivity. We further examined the expression of a group of 
proteins related to chemosensitivity by western blot analysis. 
No difference in expression of clusterin, Mdm2, Bcl-2, Bcl-xL, 
Figure 1. Effect of restoration of FGFR2IIIb on PC-3 cells. (A) FGFR2IIIb induced a decrease in cell viability. Cell viability was assessed in the FGFR2IIIb-
transfected PC-3 cells (PC-3R2IIIb) and vector control-transfected cells (PC-3neo) with the MTT assay. Cultures of 1,000 PC-3 cells were incubated in 
OPTI-MEM1 medium containing 5% heat-inactivated FBS. Representative results of three trials are shown. Data are presented as the mean ± SD of the OD 
570 nm. An asterik indicates a significant decrease in cell viability relative to the PC-3 cells transfected with the vector alone (P<0.05, Mann-Whitney U 
test). (B) Selective decrease in expression of N-cadherin and vimentin in PC-3R2IIIb cells. Markers of epithelial-to-mesenchymal transition were analyzed by 
western blot analysis. 
Figure 2. FGFR2IIIb increases the chemosensitivity of PC-3 cells particularly to docetaxel. Cell survival of PC-3neo and PC-3R2IIIb cells following treatment 
with various doses of chemotherapeutic agents over time was compared with MTT assay. The cells were treated with (A and B) 5-fluorouracil, (C and D) 
cisplatin, (E and F) zoledronic acid and (G and H) docetaxel. Representative results of three trials are shown. Data are presented as the mean ± SD of the OD 
570 nm. 
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CYP3A4, MDR1 and p53 was observed between the PC-3neo 
and PC-3R2IIIb cells. However, enhanced expression of p21 
and suppressed expression of survivin and XIAP were evident 
in the PC-3R2IIIb cells compared to the PC-3neo cells (Fig. 4).
Although p21 is a cell cycle inhibitor and differentiation 
promoter that works in conjunction with FGFRIIIb, it has also 
been reported to dampen apoptosis and therefore sensitivity to 
cancer chemotherapy (26). To shed light on this, we used an 
siRNA approach to knockdown p21 and examined the effect 
on cell proliferation, viability and chemosensitivity. Western 
blotting showed that the transfected siRNA decreased the level 
of p21 protein (Fig. 5A) without influence on PC-3R2IIIb cell 
Figure 3. FGFR2IIIb enhances expression of caspase-3 in PC-3 cells exposed to chemotherapeutic agents. Expression of caspase-3 in PC-3 cells treated with 
anticancer drugs was analyzed by western blot analysis. (A) 5-fluorouracil, (B) cisplatin, (C) zoledronic acid and (D) docetaxel. The expression of caspase-3 
was increased in a dose-dependent manner by treatment with docetaxel. A cleaved form of caspase-3 also emerged following the docetaxel treatment.
Figure 4. Effect of FGFR2IIIb restoration on proteins related to docetaxel chemosensitivity. Expression of proteins was analyzed by western blot analysis.
Figure 5. Effect of p21 expression on chemosensitivity. (A) Knockdown of p21. Western blot analysis of p21 expression in PC-3R2IIIb cell lines with p21 siRNA 
(PC-3R2IIIb siRNA1) or control scrambled siRNA (PC-3R2IIIb control) transfection. (B) Effect of p21 knockdown on cell number. (C) Effect of p21 expression 
on chemosensitivity. MTT assay was performed on both p21 siRNA-transfected PC-3R2IIIb cells and control scrambled siRNA-transfected PC-3R2IIIb cells 
after treatment with 0.1 µM docetaxel.
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proliferation (Fig. 5B). However, we observed that the knock-
down of p21 did contribute to a significant suppression of the 
viability of the PC-3R2IIIb cells in the presence of docetaxel 
(Fig. 5C).
Discussion
In the present study, we investigated the effect of FGFR2IIIb 
on the chemosensitivity of CRPC cells. To the best of our 
knowledge, this study is the first to report that restoration of 
FGFR2IIIb in CRPC cells may induce differentiation and at 
the same time enhance chemosensitivity through acceleration 
of the induction of apoptosis. It is well known that cancer 
cells break the basic rules of behavior by which homeostasis 
and normal function are maintained in normal tissues. Since 
cancer cells are genetically unstable to different degrees 
within a population, they evolve resistance when subjected to 
the selective pressures of irradiation or anticancer agents that 
target the defects in control of cell death and differentiation. 
The roles in homeostasis between cellular compartments in 
prostate tissues have been reported for FGFR2IIIb. Among 
prostate cancer cell lines, loss of epithelial cell FGFR2IIIb 
expression has been demonstrated in cell lines with high 
growth rates and castration-resistant cellular proliferation 
and other tumorigenic properties (15-21). We already showed 
that restoration of the FGFR2IIIb signaling pathway induces 
apoptosis (18) and enhances radiosensitivity in prostate cancer 
cells (27). On the basis of these findings, we hypothesized that 
the presence of a signaling pathway related to FGFR2IIIb 
could contribute to the efficacy of anticancer agents in PC-3 
cells particularly through the induction of apoptosis.
In the present study, PC-3 cells stably transfected with 
FGFR2IIIb showed not only the growth-suppressive effect 
as demonstrated in a previous report (Fig. 1A) (18) concur-
rent with the decreased expression of mesenchymal markers, 
N-cadherin and vimentin, compared to that in control PC-3neo 
cells that did not express FGFR2IIIb (Fig. 1B). These results 
indicate the possibility that restoration of FGFR2IIIb might 
reverse in part the epithelial-to-mesenchymal transition 
(EMT) that presumably has occurred in PC-3 cells. In essence 
FGFRIIIb may induce a mesenchymal-to-epithelial transition 
of sorts. Although EMT is a critical process in normal embry-
onic development, it is also associated with cancer progression 
and metastasis (28). Several studies have shown that EMT is 
associated with resistance to chemotherapy and irradiation 
(28,29).
Restoration of FGFR2IIIb increased the sensitivity to 
chemotherapeutic agents in the prostate cancer cells. The 
efficacy of the expression of FGFR2IIIb in enhancement of 
chemosensitivity depended on the choice of the chemothera-
peutic agent. We examined the chemosensitivity in prostate 
cancer cells using four drugs with different molecular and 
pharmacologic mechanisms of tumor suppression. The 
enhancement of chemosensitivity by restoration of FGFR2IIIb 
was most dramatic with docetaxel (Figs. 2 and 3). Docetaxel 
functions as an inhibitor of microtubular depolymeriza-
tion (30). In addition to microtubular dynamics, multiple 
cellular pathways involving apoptosis, inflammation, angio-
genesis, signaling intermediaries, and drug efflux pumps 
have been implicated in the chemosensitivity of docetaxel 
(31). Previous and present data indicate that the FGFR2IIIb 
signaling pathway induces apoptosis and furthermore might 
suppress EMT or at least reverse it, which has been reported to 
prevent the apoptosis of cancer cells and to induce resistance 
to chemotherapy (29,32). We then focused the investigation 
on changes in apoptosis-related molecules. Expression of 
survivin, XIAP and p21 was different between the PC-3R2IIIb 
and PC-3neo cells as shown in Fig. 4. Survivin and XIAP are a 
family of inhibitors of apoptosis proteins (IAPs) that promote 
cell survival by inhibiting the caspase cascade and apop-
tosis (31,33). Survivin and XIAP are the most studied IAPs 
with regard to resistance to anticancer agents. Previous studies 
in prostate cancer cells have shown that inhibition of survivin 
by use of the inhibitory agent antisense and adenoviral infec-
tion enhances the sensitivity to docetaxel (34), etoposide (35) 
and paclitaxel (36). Furthermore, overexpression of XIAP 
leads to chemoresistance (37) and their inhibition improves 
chemosensitivity (38). From these reports, the neutralization 
of anti-apoptotic effects through molecular mechanisms 
involving survivin and XIAP might have a strong effect on 
sensitizing prostate cancer cells to treatment with anticancer 
agents. Taken together, our results point to the possibility that 
the induction of apoptosis through FGFR2IIIb signaling might 
be associated with decreased expression of survivin and XIAP. 
The restoration of FGFR2IIIb might enhance the sensitivity of 
prostate cancer cells to docetaxel by these mechanisms.
p21 is a negative regulator of cell-cycle progression in the 
DNA damage response, and overexpression of p21 can result 
in cell-cycle arrest in either G1, G2 or the S-phase of the cell 
cycle (26). The role of p21 in the effect of anticancer agents is 
controversial and may depend on cancer cell type and cellular 
context (26). Whereas several studies have shown that p21 has 
antiapoptotic effects and is associated with chemoresistance 
in cancer cells, other studies have reported p21 as a factor 
that enhances apoptosis (26). We found that the expression 
of p21 in PC-3R2IIIb was higher than that in PC-3neo cells 
(Fig. 5). This indicated that FGFR2IIIb enhances p21 and thus 
might contribute to the cell population growth limiting effects 
observed elsewhere. We then examined whether FGFR2IIIb 
enhanced apoptosis through induction of p21 expression or 
whether p21 was induced in response to an apoptotic signal 
transduced by overexpression of FGFR2IIIb. To clarify this 
point, p21 was knocked down in PC-3 cells overexpressing 
FGFR2IIIb. As a result, the chemosensitivity to docetaxel 
was enhanced by knockdown of p21 (Fig. 5). This suggested 
that in context of the prostate cancer cell model used here, 
p21 induced by FGFR2IIIb may have anti-apoptotic activity in 
addition to its effects on cell cycling.
Among the anticancer agents examined in the present 
study, FGFR2IIIb enhanced the effect of docetaxel most 
dramatically in the prostate cancer cells. Docetaxel is 
commonly used as a chemotherapy regimen for CRPC in 
the clinic (5). It is important to identify strategies to boost 
the efficacy of docetaxel and other chemotherapeutic agents 
as well as identify biomarkers for chemosensitivity with the 
aim to avoid unwarranted toxicities in patients who will not 
benefit from treatment. In addition to docetaxel and the agents 
studied here, several new chemotherapeutic agents for prostate 
cancer have been developed. It will be interesting to determine 
molecular mechanisms and associated biomarkers involved 
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in the sensitivity to these agents and the potential role of the 
FGFR2IIIb pathway and its endpoints on the efficacy of these 
new strategies for CRPC.
In conclusion, FGFR2IIIb may be a key epithelial cell 
signaling system associated with the sensitivity of anticancer 
agents in CRPC cells. We propose that this may be due to its 
concurrent promotion of tumor cell mesenchymal-to-epithelial 
properties and apoptotic pathways. FGFR2IIIb, its specific 
pathways and endpoints may be a useful novel biomarker to 
predict chemosensitivity in CRPC. Clinical studies using the 
results here as a guide will be required to translate the manipu-
lation of FGFR2IIIb in CRPC into clinical use.
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